Gilead Sciences Business Model Canvas

Gilead’s core R&D centers on discovering and clinically testing novel molecules, from target ID to managing multi‑phase global trials; R&D spend was $6.2B in 2024 (≈18% of revenue) and remains focused in 2025 on expanding Trodelvy indications and advancing long‑acting HIV regimens with multiple Phase 2/3 studies underway.

Gilead spends heavily on regulatory affairs to secure approvals from the FDA, EMA and others, managing clinical dossiers and post‑market safety; in 2024 the company reported R&D plus SG&A of about $9.6B, much of which supports regulatory and compliance functions. Navigating shifting laws and pharmacovigilance demands—e.g., routine safety reporting and electronic submissions—remains a continuous, resource‑intensive activity across dozens of jurisdictions.

Gilead’s most valuable resource is its patent portfolio covering antivirals (HIV, hepatitis C) and oncology drugs, which enabled $24.4B revenue in 2024 and gross margins near 70% for core franchises. These patents give timed market exclusivity driving high profits; in 2025 management focuses on mitigating a patent cliff for older products and filing new patents for long-acting formulations (e.g., cabotegravir extensions).

Gilead operates state-of-the-art research centers and labs for genetic engineering, chemical synthesis, and biological testing, supporting >1,200 R&D staff and annual R&D spend of $5.0B in 2024 to speed candidate selection and IND filings.

Gilead delivers the gold-standard HIV care via single-tablet regimens such as Biktarvy (>$5.5B sales in 2024) that combine high efficacy and low side effects, driving market share. By 2025 the focus shifted to long-acting injectables—reducing daily pill burden and improving adherence—helping Gilead sustain leadership in a global HIV market worth ~$40B annually.

Gilead offers short-course direct-acting antivirals (DAAs) that achieve >95% sustained virologic response (functional cure) for hepatitis C across genotypes, cutting lifetime HCV-related costs by an estimated $50k–$200k per patient by avoiding cirrhosis, liver failure, and transplant. In 2024 Gilead retained ~40% HCV market share by promoting pan-genotypic, simplified regimens with minimal monitoring.

Gilead deploys ~1,200 Medical Science Liaisons (MSLs) globally (2025 headcount est.), who cultivate peer-to-peer ties with KOLs and specialists, delivering clinical data and answering technical queries so physicians make evidence-based prescribing choices; in 2024 Gilead spent $3.1B on R&D and medical affairs to support this science-led model, prioritizing trust and high-quality evidence over traditional sales tactics.

Gilead runs patient support programs that help navigate insurance and offer co-pay assistance—programs that in 2024 supported over 200,000 patients and provided roughly $1.1 billion in patient assistance, reducing financial barriers to therapy and improving adherence; this support boosts long-term loyalty and correlates with better outcomes, especially in HIV and HCV where adherence drives viral suppression rates above 90% in treated cohorts.

The vast majority of Gilead’s products move through large wholesalers—AmerisourceBergen, Cardinal Health, McKesson—who in 2024 handled over 70% of U.S. prescription distribution, letting Gilead reach 100,000+ pharmacies and 5,000+ hospitals without owning delivery fleets. These partners absorb logistics costs and complexity, supporting Gilead’s 2024 product revenue of $23.6 billion by enabling rapid, scalable global fulfillment.

Gilead uses specialty pharmacies for complex products like CAR-T and oncology drugs, ensuring cold-chain logistics and trained patient counseling; in 2024 specialty distribution managed over 60% of biotech injectables so this channel protects product integrity end-to-end. These pharmacies add clinical support and reimbursement navigation for high-cost treatments—Gilead’s cell therapy unit targets list prices above $400,000, so specialty handling lowers spoilage and adherence risk.

Patients with chronic viral infections include an estimated 38 million people living with HIV, ~296 million with chronic Hepatitis B, and ~58 million with Hepatitis C globally, driving steady, recurring demand for Gilead’s antiviral portfolio and accounting for a large share of its ~$27.3B antiviral revenue in 2024. By 2025, aging HIV cohorts increasingly need regimens with fewer long-term metabolic side effects, shifting prescribing toward newer, safer therapies.

This segment covers patients with cancers like breast cancer and lymphomas who have failed standard therapies and seek novel biologics or cell therapies; Gilead’s oncology revenue rose to $4.2B in 2024, driven by Yescarta (CAR-T) expansion and pipeline launches.

R&D is Gilead Sciences largest cost, covering scientist salaries, clinical trials, and lab supplies; the company spent about $5.5 billion on R&D in 2024 and continued allocating billions in 2025 to replenish the pipeline and offset looming HIV and HCV patent expirations. This high-risk, high-reward investment funds early-stage discovery and late-stage trials—critical to sustaining revenue as existing products face generic competition.

Manufacturing and supply chain costs cover operation of high-tech plants, raw materials, and global logistics; in 2024 Gilead spent about $3.1B on cost of sales and manufacturing-related expenses, reflecting complex biologics production. Cell therapy (CAR-T) manufacturing is costlier—per-patient COGS can exceed $150k due to personalized batches and rapid turnaround—and Gilead budgets for a diversified supplier base to reduce disruption risk.

Biktarvy and Descovy drive Gilead’s HIV sales, producing about $12.3 billion in 2024 product revenues and underpinning high-margin, recurring cash flow from a durable patient base on daily or periodic regimens.

By late 2025, long-acting injectables added a premium revenue layer, capturing ~8–12% of HIV segment sales and boosting average selling prices and patient retention.

Revenue from oncology products, led by Trodelvy (sacituzumab govitecan), rose sharply—Trodelvy brought in about $2.6 billion in 2024 and helped oncology sales reach roughly $3.1 billion, making oncology a fast-growing share of Gilead’s $27.4 billion 2024 revenue; high-priced biologics reflect clinical value and R&D complexity.